Survodutide

Mechanism

GLP-1 receptor agonism in the brain reduces energy intake while hepatic glucagon receptor agonism raises energy expenditure.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Body weight reduction
• MASH and fibrosis trials
• Beta-cell function research

Figures

Every figure below is replotted by this site from values published in the cited paper's text or tables — the numbers are the study's, the drawing is ours, and the evidence rung on each image is the rung of its source.

Half-life, storage & sport

Elimination half-life

not on file — No primary source stating an elimination half-life could be retrieved. Survodutide is unapproved, so there is no label and no regulatory assessment. Two human phase 1 pharmacokinetic studies are published, but neither abstract states a half-life and both full texts are paywalled with no open-access copy. Figures quoted in review articles are secondary and were not used.

Storage

not on file — no stability record on file — investigational, no label.

In sport (WADA 2026)

Prohibited, at all times — S0 catch-all. the list Not named; investigational, no approval for human therapeutic use.

Literature on file 10

• human observational
  Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. graded on: a secondary or post-hoc analysis — read from the indexed abstract — “post hoc”
• human RCT
  Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial. graded on: a phase 2b/3 trial — “Phase 3 SYNCHRONIZE-JP Trial”
• review or editorial
  Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. graded on: indexed as "Review" - secondary literature, not a study — “Review”
• review or editorial
  How does survodutide work? Plain language review of a potential new medication for obesity and liver disease. graded on: indexed as "Review" - secondary literature, not a study — “Review”
• human RCT
  Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH. graded on: a phase 2 trial — “phase 2 trial”
• human RCT
  NCT04771273: Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis. graded on: randomised and placebo-controlled — “Randomized, 48 Weeks, Dose-ranging, Placebo-controlled”

Not graded

4 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  NCT06066515: A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes graded on: NCT06066515 is completed and has posted no results - a registration, not a reported outcome — “NCT06066515”
• not graded
  NCT06066528: A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus graded on: NCT06066528 is completed and has posted no results - a registration, not a reported outcome — “NCT06066528”
• not graded
  NCT06077864: A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD graded on: NCT06077864 is completed and has posted no results - a registration, not a reported outcome — “NCT06077864”
• not graded
  NCT06176365: A Phase III, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of Survodutide Administered Subcutaneously Compared With Placebo in Patients With Obesity Disease in Japanese graded on: NCT06176365 is completed and has posted no results - a registration, not a reported outcome — “NCT06176365”

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data titration common nothing on file either way

  A 0.6 mg to 4.8 mg weekly ladder over roughly 20 weeks, escalating every 4 weeks, is circulated as the standard survodutide protocol; some vendor pages extend it to 6 mg.

  0.6 mg to 4.8 mg over ~20 weeks

  On the record No dosing record exists on file for survodutide; the ladder is reconstructed from trial arms by vendor pages.

  Source 1 · Source 2

• unverified community data storage common nothing on file either way

  Vendor reconstitution charts circulate 5 mg vial plus 2 mL bacteriostatic water (2.5 mg/mL) as the standard preparation.

  Add 2 mL of bacteriostatic water to the 5 mg vial. Resulting concentration: 2.5 mg/mL

  On the record Nothing on file; survodutide has no reconstitution or vial-format record.

  Source 1 · Source 2

• unverified community data storage common contradicts the record

  Vendor pages assert refrigerated 28-day use as 'the documented standard' for reconstituted survodutide, though no stability document exists for grey-market vials.

  Refrigeration and use within 28 days is the documented standard

  On the record Storage on file: no stability record — investigational, no label. Calling 28 days 'documented' overstates what exists.

  Source 1

• unverified community data benefit common agrees with the record

  The phase 2 GI adverse-event rate (75% versus 42% placebo) and up to 18.7% weight loss at 4.8 mg are circulated on vendor pages as the expected profile.

  Phase 2 participants receiving 4.8 mg weekly lost up to 18.7% of body weight over 46 weeks

  On the record Benefits on file are body-weight reduction, MASH and fibrosis trials, and beta-cell function research; the specific percentages need checking against the cited trial.

  Source 1

Identity

PubChem CID 168429725 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 168429725, the identifier on this record.

Molecular weight

4232

Molecular formula

C192H289N47O61

PubChem CID

168429725

InChI key

MEDXQFAHWBMVIM-YIUAJOCSSA-N

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C7(CCC7)NC(=O)[C@H](CC8=CNC=N8)N

InChI

InChI=1S/C192H289N47O61/c1-12-103(6)157(186(295)221-122(170(279)227-134(83-113-88-203-119-48-34-33-47-117(113)119)177(286)223-128(77-101(2)3)173(282)219-126(66-70-153(261)262)172(281)232-140(97-242)183(292)210-104(7)160(197)269)51-37-40-75-201-146(252)90-205-147(253)91-206-165(274)138(95-240)215-149(255)93-208-166(275)139(96-241)214-148(254)92-204-144(250)68-64-127(189(298)299)213-145(251)53-31-23-21-19-17-15-13-14-16-18-20-22-24-32-54-151(257)258)237-181(290)132(79-109-43-27-25-28-44-109)226-179(288)136(86-155(265)266)228-168(277)120(49-35-38-73-193)216-162(271)106(9)211-161(270)105(8)212-167(276)123(52-41-76-202-191(198)199)217-171(280)125(65-69-152(259)260)220-178(287)135(85-154(263)264)229-174(283)129(78-102(4)5)222-175(284)130(81-111-55-59-115(247)60-56-111)224-169(278)121(50-36-39-74-194)218-184(293)141(98-243)233-176(285)131(82-112-57-61-116(248)62-58-112)225-180(289)137(87-156(267)268)230-185(294)142(99-244)234-188(297)159(108(11)246)238-182(291)133(80-110-45-29-26-30-46-110)231-187(296)158(107(10)245)236-150(256)94-207-164(273)124(63-67-143(196)249)235-190(300)192(71-42-72-192)239-163(272)118(195)84-114-89-200-100-209-114/h25-30,33-34,43-48,55-62,88-89,100-108,118,120-142,157-159,203,240-248H,12-24,31-32,35-42,49-54,63-87,90-99,193-195H2,1-11H3,(H2,196,249)(H2,197,269)(H,200,209)(H,201,252)(H,204,250)(H,205,253)(H,206,274)(H,207,273)(H,208,275)(H,210,292)(H,211,270)(H,212,276)(H,213,251)(H,214,254)(H,215,255)(H,216,271)(H,217,280)(H,218,293)(H,219,282)(H,220,287)(H,221,295)(H,222,284)(H,223,286)(H,224,278)(H,225,289)(H,226,288)(H,227,279)(H,228,277)(H,229,283)(H,230,294)(H,231,296)(H,232,281)(H,233,285)(H,234,297)(H,235,300)(H,236,256)(H,237,290)(H,238,291)(H,239,272)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,298,299)(H4,198,199,202)/t103-,104+,105-,106-,107+,108+,118-,120-,121-,122+,123-,124-,125-,126+,127?,128+,129-,130+,131-,132-,133-,134+,135-,136-,137-,138+,139+,140+,141-,142-,157-,158-,159-/m0/s1

Listed prices 22

What 21 shops we track listed for Survodutide, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record